Abbott Laboratories ABT NYSE

Abbott Laboratories (ABT) reported total assets of $86.71B and total liabilities of $33.94B for quarter ending 2025-12-31, resulting in total equity of $52.77B.

The company held $8.94B in cash and short-term investments. Total debt stood at $15.07B, with net debt of $6.55B. The Debt-to-Equity (D/E) ratio was 0.29 (conservative).

Current ratio is 1.58, indicating strong short-term liquidity. Interest coverage is 53.6x (strong).

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.29, current ratio of 1.58, interest coverage 53.6x — balance sheet is strong
• MOAT (86/100) — Total assets $86.71B and equity $52.77B support the company's competitive scale
• VALUE (58/100) — Debt-to-Equity 0.29 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.